BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, Second-Generation Fumarate Derivative – Fumapharm/Biogen Idec

By Adis International Limited  

Drugs in R&D, Vol. 6, Iss. 4, 2005-01 ,pp. : 229-230

Adis International

Access to resources Recommend Favorite

Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM

By Havrdova Eva   Hutchinson Michael   Kurukulasuriya Nuwan C   Raghupathi Kartik   Sweetser Marianne T   Dawson Katherine T   Gold Ralf  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 15, 2013-10 ,pp. : 2145-2156

Informa Healthcare

Access to resources Recommend Favorite

A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency

By Staidle Jonathan P   Dabade Tushar S   Feldman Steven R  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 13, 2011-09 ,pp. : 2041-2054

Informa Healthcare

Access to resources Recommend Favorite

Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis: An Open-Label Extension of a Phase IIIb Trial

By Hamilton Tiffani  

Drug Safety, Vol. 31, Iss. 8, 2008-01 ,pp. : 715-726

Adis International

Access to resources Recommend Favorite

The Burden of Moderate to Severe Psoriasis: An Overview

By Raho Giovanna  

PharmacoEconomics, Vol. 30, Iss. 11, 2012-11 ,pp. : 1005-1013

Adis International

Access to resources Recommend Favorite